Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Endocrine dysfunction in patients receiving immunotherapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.01.20
Views: 259

Sherwin Criseno - University Hospitals Birmingham, Birmingham, UK

Sherwin Criseno speaks to ecancer at UKONS 2019 in Telford about navigating the endocrinopathy puzzle in patients receiving immunotherapy.

Criseno explains that endocrinopathy is poorly understood in the field of immunotherapy due to it being quite rare and the presentation of patients receiving immunotherapy can be vague. He outlines the case study discussed in his session and some of the red flags they managed to recognise.

He also proposes ways for the management of these patients to improve - including education, networking and looking at best practice elsewhere.


Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation